Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (ACCESS) (ITN034AI)
收藏NIAID Data Ecosystem2026-05-10 收录
数据链接：
官方服务：
资源简介：
The ACCESS study is a multicenter, randomized, double-blind, controlled Phase II clinical trial designed to rigorously evaluate the efficacy and safety of CTLA4Ig (abatacept) in combination with cyclophosphamide, compared to cyclophosphamide alone, for the treatment of lupus nephritis in individuals diagnosed with systemic lupus erythematosus (SLE).
创建时间：
2025-12-18
